公开(公告)号：US20240343716A1

公开(公告)日：2024-10-17

申请号：US18435619

申请日：2024-02-07

申请人： ABIVAX ,  CENTRE NATIONAL DE RECHERCHE SCIENTIFIQUE ,  INSTITUT CURIE ,  UNIVERSITE DE MONTPELLIER

发明人： Jamal TAZI ,  Florence MAHUTEAU ,  Pierre ROUX ,  Romain NAJMAN ,  Didier SCHERRER ,  Carsten BROCK ,  Nathalie CAHUZAC ,  Gilles GADEA ,  Noelie CAMPOS ,  Aude GARCEL ,  Julien SANTO

IPC分类号： C07D413/04 ,  A61K31/4709 ,  A61K31/4985 ,  C07D213/74 ,  C07D215/38 ,  C07D215/42 ,  C07D215/46 ,  C07D217/02 ,  C07D241/44 ,  C07D401/12 ,  C07D403/12

CPC分类号： C07D413/04 ,  A61K31/4709 ,  A61K31/4985 ,  C07D213/74 ,  C07D215/38 ,  C07D215/42 ,  C07D215/46 ,  C07D217/02 ,  C07D241/44 ,  C07D401/12 ,  C07D403/12

摘要： The manufacture and use of compounds of formula (Ia) or a pharmaceutically acceptable salt thereof for preventing, inhibiting or treating cancer, AIDS and/or premature aging. The compounds of formula (Ia) being:




where:



R independently represents a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —CN group, a hydroxyl group, a —COOR1 group, a (C1-C3)fluoroalkyl group, a —NO2 group, a —NR1R2 group, or a (C1-C3)alkoxy group;
R′ is a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —NO2 group, a (C1-C3)alkoxy group, or a —NR1R2 group; and
R1 and R2 are a hydrogen atom or a (C1-C3)alkyl group.

公开(公告)号：US20180127353A1

公开(公告)日：2018-05-10

申请号：US15840847

申请日：2017-12-13

申请人： ABIVAX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT CURIE ,  UNIVERSITE DE MONTPELLIER

发明人： Didier SCHERRER ,  Jamal TAZI ,  Romain NAJMAN ,  Florence MAHUTEAU ,  Pierre ROUX

IPC分类号： C07C237/30 ,  C07D233/61 ,  C07D401/12 ,  C07D249/06 ,  C07D233/64 ,  C07D213/36 ,  A61K31/5377 ,  A61K31/496 ,  A61K31/495 ,  A61K31/4545 ,  A61K31/4439 ,  A61K31/4409 ,  A61K31/4192 ,  A61K31/417 ,  A61K31/4164 ,  A61K31/167 ,  A61K31/166 ,  C07D213/38

CPC分类号： C07C237/30 ,  A61K31/166 ,  A61K31/167 ,  A61K31/4164 ,  A61K31/417 ,  A61K31/4192 ,  A61K31/4409 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/495 ,  A61K31/496 ,  A61K31/5377 ,  C07D213/36 ,  C07D213/38 ,  C07D233/61 ,  C07D233/64 ,  C07D249/06 ,  C07D401/12

摘要： The present disclosure relates to compound (I) wherein R1 and R2 independently represent a hydrogen atom, a (C1-C4)alkoxy group, a fluoro(C1-C4)alkoxy group, a hydroxyl group, a benzyloxy group, a di(C1-C4)alkylamino group, a pyridyl-vinyl group, a pyrimidinyl-vinyl group, a styryl group, or a —NHCOphenyl group; R3, R4 and R5 independently represent a hydrogen atom, a (C1-C4)alkyl group, a CONHR6 group, a —CONR7R8 group, a —SO2NHR6 group, or a heteroaryl group optionally substituted by a halogen atom, a —(CH2)nNR7R8 group or a hydroxy(C1-C4)alkyl group; R6 represents a hydrogen atom, a —(CHR9)m(CH2)nNR7R8 group or a (C1-C6)alkyl group optionally substituted by a hydroxyl group; or anyone of its pharmaceutically acceptable salt, for use in a method for preventing, inhibiting or treating a disease in a patient suffering thereof, said disease involving a deregulated p53. Some of said compounds are new and also form part of the disclosure.

公开(公告)号：US20170226095A1

公开(公告)日：2017-08-10

申请号：US15486836

申请日：2017-04-13

申请人： ABIVAX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT CURIE ,  UNIVERSITE DE MONTPELLIER

发明人： Jamal TAZI ,  Florence MAHUTEAU ,  Pierre ROUX ,  Romain NAJMAN ,  Didier SCHERRER ,  Carsten BROCK ,  Nathalie CAHUZAC ,  Gilles GADEA ,  Noelie CAMPOS ,  Aude GARCEL ,  Julien SANTO

IPC分类号： C07D413/04 ,  C07D217/02 ,  C07D401/12 ,  C07D403/12 ,  C07D215/38 ,  C07D241/44

CPC分类号： C07D413/04 ,  A61K31/4709 ,  A61K31/4985 ,  C07D213/74 ,  C07D215/38 ,  C07D215/42 ,  C07D215/46 ,  C07D217/02 ,  C07D241/44 ,  C07D401/12 ,  C07D403/12

摘要： The manufacture and use of compounds of formula (Ia) or a pharmaceutically acceptable salt thereof for preventing, inhibiting or treating cancer, AIDS and/or premature aging. The compounds of formula (Ia) being: where: R independently represents a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —CN group, a hydroxyl group, a —COOR1 group, a (C1-C3)fluoroalkyl group, a —NO2 group, a —NR1R2 group, or a (C1-C3)alkoxy group; R′ is a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —NO2 group, a (C1-C3)alkoxy group, or a —NR1R2 group; and R1 and R2 are a hydrogen atom or a (C1-C3) alkyl group.

公开(公告)号：US20220127253A1

公开(公告)日：2022-04-28

申请号：US17327079

申请日：2021-05-21

申请人： ABIVAX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT CURIE ,  UNIVERSITE DE MONTPELLIER

发明人： Jamal TAZI ,  Florence MAHUTEAU ,  Pierre ROUX ,  Romain NAJMAN ,  Didier SCHERRER ,  Carsten BROCK ,  Nathalie CAHUZAC ,  Gilles GADEA ,  Noelie CAMPOS ,  Aude GARCEL ,  Julien SANTO

IPC分类号： C07D413/04 ,  C07D215/38 ,  C07D241/44 ,  C07D401/12 ,  C07D403/12 ,  C07D217/02 ,  A61K31/4709 ,  A61K31/4985 ,  C07D213/74 ,  C07D215/42 ,  C07D215/46

摘要： The manufacture and use of compounds of formula (Ia) or a pharmaceutically acceptable salt thereof for preventing, inhibiting or treating cancer, AIDS and/or premature aging. The compounds of formula (Ia) being: where: R independently represents a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —CN group, a hydroxyl group, a —COOR1 group, a (C1-C3)fluoroalkyl group, a —NO2 group, a —NR1R2 group, or a (C1-C3)alkoxy group; R′ is a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —NO2 group, a (C1-C3)alkoxy group, or a —NR1R2 group; and R1 and R2 are a hydrogen atom or a (C1-C3) alkyl group.

公开(公告)号：US20200239444A1

公开(公告)日：2020-07-30

申请号：US16848916

申请日：2020-04-15

申请人： ABIVAX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT CURIE ,  UNIVERSITE DE MONTPELLIER

发明人： Pierre ROUX ,  Florence MAHUTEAU ,  Romain NAJMAN ,  Gilles GADEA ,  Jamal TAZI ,  Didier SCHERRER ,  Carsten BROCK ,  Nathalie CAHUZAC

IPC分类号： C07D401/14 ,  C07D239/42 ,  C07D401/12 ,  C07D213/75

摘要： A compound of formula (I): wherein A and A′ independently represent a phenylene group or a pyridylene group; R2 is a hydrogen atom or a (C1-C4)alkyl group; R3 is a 2-pyridyl group, 3-pyridyl group, a 4-pyridyl group, a 2-pyrimidinyl group, a 4-pyrimidinyl group or a 5-pyrimidinyl group; R4 is a carbonyl group or a sulfonyl group; and R5 is a —NH—(CH2)a—NR6R7 group or a 4-methylpiperazinyl group, with a being an integer from 1 to 4, R6 and R7 representing independently a (C1-C4)alkyl group, or R6 and R7 together with the nitrogen atom to which they are linked forming a heterocycle group which is chosen among a 4-methylpiperazinyl group, a morpholino group, a pyrrolidinyl group and a piperidino group; or any one of its pharmaceutically acceptable salt.

公开(公告)号：US20180222888A1

公开(公告)日：2018-08-09

申请号：US15946120

申请日：2018-04-05

申请人： ABIVAX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT CURIE ,  UNIVERSITE DE MONTPELLIER

发明人： Pierre ROUX ,  Florence MAHUTEAU ,  Romain NAJMAN ,  Gilles GADEA ,  Jamal TAZI ,  Didier SCHERRER ,  Carsten BROCK ,  Nathalie CAHUZAC

IPC分类号： C07D401/14 ,  C07D239/42 ,  C07D213/75 ,  C07D401/12

摘要： The present invention relates to a compound of formula (I): wherein A and A′ independently represent a phenylene group or a pyridylene group; R2 is a hydrogen atom or a (C1-C4)alkyl group; R3 is a 2-pyridyl group, 3-pyridyl group, a 4-pyridyl group, a 2-pyrimidinyl group, a 4-pyrimidinyl group or a 5-pyrimidinyl group; R4 is a carbonyl group or a sulfonyl group; and R5 is a —NH—(CH2)a—NR6R7 group or a 4-methylpiperazinyl group, with a being an integer from 1 to 4, R6 and R7 representing independently a (C1-C4)alkyl group, or R6 and R7 together with the nitrogen atom to which they are linked forming a heterocycle group which is chosen among a 4-methylpiperazinyl group, a morpholino group, a pyrrolidinyl group and a piperidino group; or any one of its pharmaceutically acceptable salt.

公开(公告)号：US20150315173A1

公开(公告)日：2015-11-05

申请号：US14432328

申请日：2013-09-30

申请人： ABIVAX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT CURIE ,  UNIVERSITE DE MONTPELLIER

发明人： Pierre ROUX ,  Florence MAHUTEAU ,  Romain NAJMAN ,  Gilles GADEA ,  Jamal TAZI ,  Didier SCHERRER ,  Carsten BROCK ,  Nathalie CAHUZAC

IPC分类号： C07D401/14 ,  C07D239/42 ,  C07D401/12 ,  C07D213/75

CPC分类号： C07D401/14 ,  C07D213/75 ,  C07D239/42 ,  C07D401/12

摘要： The present invention relates to a compound of formula (I): wherein A and A′ independently represent a phenylene group or a pyridylene group; R2 is a hydrogen atom or a (C1-C4)alkyl group; R3 is a 2-pyridyl group, 3-pyridyl group, a 4-pyridyl group, a 2-pyrimidinyl group, a 4-pyrimidinyl group or a 5-pyrimidinyl group; R4 is a carbonyl group or a sulfonyl group; and R5 is a —NH—(CH2)a—NR6R7 group or a 4-methylpiperazinyl group, with a being an integer from 1 to 4, R6 and R7 representing independently a (C1-C4)alkyl group, or R6 and R7 together with the nitrogen atom to which they are linked forming a heterocycle group which is chosen among a 4-methylpiperazinyl group, a morpholino group, a pyrrolidinyl group and a piperidino group; or any one of its pharmaceutically acceptable salt.

摘要翻译： 本发明涉及式（I）化合物：其中A和A'独立地表示亚苯基或亚吡啶基; R2是氢原子或（C1-C4）烷基; R3是2-吡啶基，3-吡啶基，4-吡啶基，2-嘧啶基，4-嘧啶基或5-嘧啶基; R4是羰基或磺酰基; 并且R 5为-NH-（CH 2）a -NR 6 R 7基或4-甲基哌嗪基，其为1至4的整数，R 6和R 7独立地表示（C 1 -C 4）烷基，或者R 6和R 7一起 与它们相连的氮原子形成选自4-甲基哌嗪基，吗啉基，吡咯烷基和哌啶子基的杂环基; 或其药学上可接受的盐中的任何一种。

公开(公告)号：US20140155436A1

公开(公告)日：2014-06-05

申请号：US14070799

申请日：2013-11-04

申请人： CENTRE NATIONAL DE RECHERCHE SCIENTIFIQUE ,  UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUES ,  INSTITUT CURIE

发明人： Jamal TAZI ,  David GRIERSON ,  Florence MAHUTEAU-BETZER ,  Pierre ROUX

IPC分类号： C07D401/12 ,  C07D213/74 ,  C07C237/30 ,  C07D249/06 ,  C07D233/64 ,  C07D213/38

CPC分类号： A61K31/166 ,  A61K31/417 ,  A61K31/4192 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/4439 ,  A61K31/4725 ,  C07C237/30 ,  C07D213/38 ,  C07D213/56 ,  C07D213/74 ,  C07D213/75 ,  C07D213/82 ,  C07D233/61 ,  C07D233/64 ,  C07D249/06 ,  C07D401/12 ,  C07D401/14

摘要： The present invention relates to a compound of one of the formulas I to XXI; a pharmaceutical composition comprising at least one such compound; and the use of at least one such compound in preparing a drug to treat, in a subject, a genetic disease resulting from at least one splicing anomaly.

摘要翻译： 本发明涉及式I至XXI之一的化合物; 包含至少一种这样的化合物的药物组合物; 以及使用至少一种这样的化合物制备药物以在受试者中治疗由至少一个拼接异常引起的遗传疾病。

公开(公告)号：US20160166519A1

公开(公告)日：2016-06-16

申请号：US14958602

申请日：2015-12-03

申请人： CENTRE NATIONALE DE RECHERCHE SCIENTIFIQUE ,  UNIVERSITE DE MONTPELLIER ,  INSTITUT CURIE

发明人： Jamal TAZI ,  David GRIERSON ,  Florence MAHUTEAU-BETZER ,  Pierre ROUX

IPC分类号： A61K31/166 ,  A61K31/4409 ,  A61K31/4725 ,  A61K31/4439 ,  A61K31/417 ,  A61K31/4406 ,  A61K31/4192

CPC分类号： A61K31/166 ,  A61K31/417 ,  A61K31/4192 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/4439 ,  A61K31/4725 ,  C07C237/30 ,  C07D213/38 ,  C07D213/56 ,  C07D213/74 ,  C07D213/75 ,  C07D213/82 ,  C07D233/61 ,  C07D233/64 ,  C07D249/06 ,  C07D401/12 ,  C07D401/14

摘要： A method of treating a disease selected from the group consisting of cancer, Duchenne muscular dystrophy, AIDS, and progeria, that includes administering to a patient in need thereof an effective quantity of at least one compound of formula (IV) or a pharmaceutically acceptable salt thereof.

摘要翻译： 一种治疗选自下组的疾病的方法，所述疾病包括癌症，杜氏肌营养不良症，艾滋病和原因，其包括向有需要的患者施用有效量的至少一种式（IV）化合物或其药学上可接受的盐 其中。

公开(公告)号：US20190022037A1

公开(公告)日：2019-01-24

申请号：US16153249

申请日：2018-10-05

申请人： CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT CURIE ,  UNIVERSITE DE MONTPELLIER

发明人： Jamal TAZI ,  David GRIERSON ,  Florence MAHUTEAU-BETZER ,  Pierre ROUX

IPC分类号： A61K31/166 ,  A61K31/4725 ,  A61K31/417 ,  A61K31/4439 ,  A61K31/4409 ,  A61K31/4406 ,  A61K31/4192

摘要： Compounds and pharmaceutically acceptable salts thereof that may be used to treat a disease, for example, Duchenne muscular dystrophy, AIDS, and progeria. The compounds and pharmaceutically acceptable salts thereof may be part of a pharmaceutical composition including a pharmaceutically acceptable support.